PROCEEDS AGREEMENTProceeds Agreement • May 3rd, 2023 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
WHEREAS, the Agent, in his capacity as a director of Seagen Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,750 shares of the Company common stock (the “Stock”) according to the below Schedule A;
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., and Baker Bros. Advisors LPLoan Agreement • May 3rd, 2023 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
For value received, Baker Bros. Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., and 667, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interest payable through the Due Date at a rate of 3.72% annually.
